Welcome to our dedicated page for Vanda Pharma SEC filings (Ticker: VNDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vanda Pharmaceuticals Inc. (VNDA) SEC filings page on Stock Titan provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. These filings offer detailed insight into how Vanda describes its commercial portfolio, clinical pipeline, financial condition, and interactions with the U.S. Food and Drug Administration.
Recent Form 8-K filings referenced by Vanda include earnings announcements and disclosures about a collaborative framework with the FDA regarding HETLIOZ (tasimelteon) and tradipitant. Through these current reports, investors can review management’s discussion of net product sales for Fanapt, HETLIOZ, and PONVORY, as well as updates on NDAs and BLAs for programs such as Bysanti, tradipitant in motion sickness, and imsidolimab in generalized pustular psoriasis.
On Stock Titan, VNDA filings are updated in near real time from EDGAR and paired with AI-powered summaries that explain the key points of lengthy documents. For annual reports on Form 10-K and quarterly reports on Form 10-Q, AI highlights sections related to Vanda’s commercial products, research and development spending, and risk factors tied to regulatory decisions and clinical trial outcomes. For current reports on Form 8-K, AI summaries focus on the specific material events being disclosed, such as financial results or significant regulatory agreements.
Users can also review other SEC forms associated with VNDA, including exhibits attached to 8-K filings that contain press releases or detailed descriptions of regulatory milestones. For investors analyzing Vanda’s work in sleep-wake disorders, psychiatric conditions, motion sickness, and rare inflammatory skin disease, these filings provide a structured view of the company’s obligations, forward-looking statements, and disclosed risks, while the AI tools on Stock Titan help make the technical language more accessible.
Vanda Pharmaceuticals Inc. reported that it has reached a collaborative framework with the U.S. Food and Drug Administration to resolve certain disputes involving its drugs HETLIOZ® (tasimelteon) and tradipitant. This means the company and the FDA have agreed on a structured approach to address outstanding regulatory disagreements related to these products.
The company announced this development in a press release dated October 1, 2025, which is referenced as an exhibit. While specific terms or outcomes are not described here, the framework focuses on moving toward resolution of the disputes regarding these two drugs.
Mihael H. Polymeropoulos, identified as President and CEO (also listed as a director and chairman), reported a purchase of 10,000 shares of Vanda Pharmaceuticals common stock on 08/07/2025 at $4.15 per share. After this purchase he beneficially owns 2,335,731 shares. The Form 4 discloses a direct insider buy by the company’s chief executive, increasing his reported stake.